Comparing the current results to its competitors, Essa Pharma Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 34.44 %, recorded in the same quarter.
Essa Pharma Inc 's Comment on Competition and Industry Peers
The prostate cancer market is characterized by intense competition among companies with substantial financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Mergers and acquisitions have led to resource concentration among fewer competitors. Several pharmaceutical therapies are approved and available, with new molecules under investigation. Approved therapies and their manufacturers include Enzalutamide (Xtandi) by Astellas and Pfizer; Abiraterone acetate (Zytiga) by Johnson & Johnson; Abiraterone acetate (Yonsa) by Sun Pharma; Sipuleucel-T (Provenge) by Valeant; Docetaxel and Cabazitaxel by Sanofi; Olaparib/abiraterone acetate (Akeega) by Johnson & Johnson; and Talazaparib (Talzenna) by Pfizer. Generic versions of Zytiga are also approved and commercially available in the U.S. ESSA considers its competitive position strong due to its product candidate's unique mechanism targeting androgen receptor activation, which may circumvent resistance pathways associated with existing hormone-related therapies. Competitors identified include Astellas, Johnson & Johnson, Pfizer, Sanofi, Sun Pharma, and Valeant.
Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients' lives.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Essa Pharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Essa Pharma inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
